Women With Pregnancy and Lactation-Associated Osteoporosis (PLO) Have Low Bone Remodeling Rates at the Tissue Level.
BONE HISTOMORPHOMETRY
PREGNANCY AND LACTATION-ASSOCIATED OSTEOPOROSIS
PREMENOPAUSAL OSTEOPOROSIS
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
30
11
2018
revised:
19
03
2019
accepted:
21
04
2019
pubmed:
28
7
2019
medline:
23
9
2020
entrez:
27
7
2019
Statut:
ppublish
Résumé
Pregnancy and lactation-associated osteoporosis (PLO) is a rare, severe, early form of osteoporosis in which young women present with fractures, usually multiple vertebral fractures, during late pregnancy or lactation. In studies of idiopathic osteoporosis (IOP) in premenopausal women, we enrolled 78 women with low-trauma fractures and 40 healthy controls, all with normal menses and no secondary cause of bone loss. In 15 of the affected women, the PLO subgroup, fractures had occurred during late pregnancy or lactation. We hypothesized that clinical, bone structural, and metabolic characteristics would differ between women with PLO and those with (non-PLO) IOP and controls. All were evaluated > 12 months postpartum, when structural and remodeling characteristics would be expected to reflect baseline premenopausal status rather than transient postpartum changes. As previously reported, affected subjects (PLO and IOP) had BMD and microarchitectural deficiencies compared to controls. Women with PLO did not differ from those with IOP in terms of age, BMI, body fat, menarcheal age, parity, or age at first pregnancy. However, women with PLO had a more severe clinical presentation than those with IOP: more fractures (5.5 ± 3.3 versus 2.6 ± 2.1; p = 0.005); more vertebral fractures (80% versus 17%; p < 0.001); and higher prevalence of multiple fractures. BMD deficits were more profound and cortical width tended to be lower in PLO. PLO subjects also had significantly lower tissue-level mineral apposition rate and bone formation rates (0.005 ± 0.005 versus 0.011 ± 0.010 mm
Identifiants
pubmed: 31348548
doi: 10.1002/jbmr.3750
pmc: PMC6744311
mid: NIHMS1026137
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1552-1561Subventions
Organisme : NIAMS NIH HHS
ID : K23 AR054127
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR049896
Pays : United States
Organisme : NIAMS NIH HHS
ID : RO1AR49896
Pays : United States
Organisme : NIAMS NIH HHS
ID : K23AR054127
Pays : United States
Organisme : FDA HHS
ID : R01 FD003902
Pays : United States
Informations de copyright
© 2019 American Society for Bone and Mineral Research.
Références
Obstet Gynecol. 1999 Jul;94(1):52-6
pubmed: 10389717
J Bone Miner Res. 1999 Jul;14(7):1167-74
pubmed: 10404017
Osteoporos Int. 2000;11(5):449-54
pubmed: 10912848
Ugeskr Laeger. 2000 Jul 3;162(27):3865-6
pubmed: 10920703
Osteoporos Int. 2001;12(10):828-34
pubmed: 11716185
Lancet. 1955 Feb 26;268(6861):431-4
pubmed: 13234409
Joint Bone Spine. 2004 Jan;71(1):84-5
pubmed: 14769530
Acta Orthop. 2005 Feb;76(1):2-13
pubmed: 15788303
J Bone Miner Res. 2006 Mar;21(3):366-73
pubmed: 16491283
Osteoporos Int. 2006;17(7):1008-12
pubmed: 16758139
Osteoporos Int. 2010 Feb;21(2):263-73
pubmed: 19455271
J Clin Endocrinol Metab. 2009 Nov;94(11):4351-60
pubmed: 19837923
Gynecol Endocrinol. 2010 Oct;26(10):725-8
pubmed: 20230328
Rheumatol Int. 2012 Mar;32(3):819-23
pubmed: 21327429
Osteoporos Int. 2012 Jan;23(1):171-82
pubmed: 21365462
J Bone Miner Res. 2011 Nov;26(11):2727-36
pubmed: 21735476
J Clin Endocrinol Metab. 2011 Oct;96(10):3095-105
pubmed: 21832117
J Bone Miner Metab. 2012 Sep;30(5):596-601
pubmed: 22105654
Ther Clin Risk Manag. 2012;8:195-9
pubmed: 22547939
J Bone Miner Res. 2013 Jan;28(1):2-17
pubmed: 23197339
Hormones (Athens). 2012 Oct-Dec;11(4):495-500
pubmed: 23422774
J Clin Endocrinol Metab. 2013 Jun;98(6):2562-72
pubmed: 23515452
J Clin Endocrinol Metab. 2013 May;98(5):1971-81
pubmed: 23543660
J Obstet Gynaecol Res. 2014 Jan;40(1):288-92
pubmed: 24102815
Arch Orthop Trauma Surg. 2014 Feb;134(2):173-9
pubmed: 24357025
Osteoporos Int. 2015 Jan;26(1):415-8
pubmed: 25138263
Osteoporos Int. 2015 Sep;26(9):2223-41
pubmed: 25939309
Calcif Tissue Int. 2015 Oct;97(4):421-5
pubmed: 26108650
Ther Clin Risk Manag. 2015 Sep 07;11:1361-5
pubmed: 26379439
Physiol Rev. 2016 Apr;96(2):449-547
pubmed: 26887676
Endocrinol Metab Clin North Am. 2017 Mar;46(1):117-133
pubmed: 28131128
Osteoporos Int. 2018 Jan;29(1):135-142
pubmed: 28965212
Clin Endocrinol (Oxf). 2018 May;88(5):652-658
pubmed: 29389010
Osteoporos Int. 2018 Jul;29(7):1643-1651
pubmed: 29594386
Arch Intern Med. 1986 Feb;146(2):386-8
pubmed: 3947197
Metab Bone Dis Relat Res. 1984;5(4):159-65
pubmed: 6738354
Nouv Presse Med. 1982 Jan 30;11(4):261-4
pubmed: 7058149
J Clin Endocrinol Metab. 1995 Jul;80(7):2210-6
pubmed: 7608281
Calcif Tissue Int. 1994 Jan;54(1):20-5
pubmed: 8118748
Br J Rheumatol. 1994 Mar;33(3):269-72
pubmed: 8156291
Clin Endocrinol (Oxf). 1993 Oct;39(4):487-90
pubmed: 8287577
JAMA. 1993 Jun 23-30;269(24):3130-5
pubmed: 8505816
QJM. 1995 Dec;88(12):865-78
pubmed: 8593546
Calcif Tissue Int. 1996 Jan;58(1):24-9
pubmed: 8825235
N Engl J Med. 1997 Aug 21;337(8):523-8
pubmed: 9262495
Clin Sci (Lond). 1998 Apr;94(4):405-12
pubmed: 9640346